For over a decade, taking a pill like Truvada every day has been the standard of care for HIV prevention efforts. In clinical trials, this type of preventive drug, called pre-exposure prophylaxis ...

You may have heard about Descovy (des-ko'-vee), a medicine approved by the FDA in 2015. Descovy is approved to treat HIV. It can also help prevent people from getting HIV through sex. People with HIV ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

An injectable drug to prevent HIV provides a substantial benefit, according to updated recommendations from the U.S. Preventive Services Task Force (USPSTF). The new recommendations for preexposure ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events. And this drug has major pros ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, ...

A national health task force’s sterling new endorsement of a long-acting injectable medication for use as HIV prevention will require health insurers to begin covering the pricey drug by 2025. Such ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo, which was approved last week by the FDA? An HIV physician, who ...